Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 29, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome

SAN RAFAEL, Calif., Dec. 29, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Ministry of Health, Labor and Welfare granted approval of the registration of...
December 24, 2014 13:15 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa

SAN RAFAEL, Calif., Dec. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced the expiration of the mandatory waiting period...
December 10, 2014 08:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome

SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Agência Nacional de Vigilancia Sanitaria (ANVISA), or the National Health...
December 10, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)

SAN RAFAEL, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for BMN...
December 09, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York

SAN RAFAEL, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst and Investor Day from 8am (ET) to 1pm (ET) on Wednesday, December 10, 2014 at The...
December 07, 2014 16:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome

SAN RAFAEL, Calif., Dec. 7, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Australian Therapeutic Goods Administration (TGA) granted approval of the...
December 03, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Analyst and Investor Day on December 10th in New York

SAN RAFAEL, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host an Analyst & Investor Day for the investment community on Wednesday, December 10, 2014...
November 24, 2014 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD) Drisapersen...
November 19, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences

Deutsche Bank BioFEST on December 2 Piper Jaffray Healthcare Conference on December 3 SAN RAFAEL, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today...
November 04, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference

SAN RAFAEL, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present at...